Literature DB >> 23332087

Liver and diabetes. A vicious circle.

Paola Loria1, Amedeo Lonardo, Frank Anania.   

Abstract

The complex and bi-directional relationship linking the liver and diabetes has recently gained intense new interest. This critical review of the published work aims to highlight the most recent basic and clinical data underlying the development of type 2 diabetes, in those with non-alcoholic fatty liver disease. Moreover, the potentially detrimental effects of type 2 diabetes in liver injury are also discussed in each of the two sections of the present paper. Fatty liver and diabetes share insulin resistance as their chief pathogenic determinant. The roles of the hypothalamus, the intestinal microbiome, white adipose tissue and inflammation are discussed in detail. Molecular insights into hepatocyte insulin resistance as the initiator of systemic insulin resistance are also presented with full coverage of the danger of fatty acids. Lipotoxicity, apoptosis, lipoautophagy, endoplasmic reticular stress response and recent developments in genetics are discussed. Closing the circle, special emphasis is given to biochemical pathways and clinical evidence supporting the role of type 2 diabetes as a risk factor for the development of progressive liver disease, including non-alcoholic steatohepatitis, cirrhosis and primary liver cancer. In conclusion, data support non-alcoholic fatty liver disease as a risk factor for the development of type 2 diabetes which is, in turn, a major contributor to progressive liver disease. This pathway leading from fatty liver to type 2 diabetes and back from the latter to the progressive liver disease is a vicious circle.
© 2012 The Japan Society of Hepatology.

Entities:  

Year:  2013        PMID: 23332087      PMCID: PMC3733501          DOI: 10.1111/j.1872-034X.2012.01031.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  141 in total

1.  Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation.

Authors:  G Perseghin; V Mazzaferro; L P Sereni; E Regalia; S Benedini; E Bazzigaluppi; A Pulvirenti; A A Leão; G Calori; R Romito; D Baratti; L Luzi
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

2.  Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats.

Authors:  Lorenzo Azzalini; Elisabet Ferrer; Leandra N Ramalho; Montserrat Moreno; Marlene Domínguez; Jordi Colmenero; Víctor I Peinado; Joan A Barberà; Vicente Arroyo; Pere Ginès; Joan Caballería; Ramón Bataller
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

3.  Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.

Authors:  Valter Donadon; Massimiliano Balbi; Francesca Valent; Angelo Avogaro
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 4.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

5.  Stress signaling in the methionine-choline-deficient model of murine fatty liver disease.

Authors:  Russell K Soon; Jim S Yan; James P Grenert; Jacquelyn J Maher
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

6.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

7.  Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease.

Authors:  Claudia O Zein; Aynur Unalp; Ryan Colvin; Yao-Chang Liu; Arthur J McCullough
Journal:  J Hepatol       Date:  2010-09-22       Impact factor: 25.083

8.  Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study.

Authors:  Maria Stepanova; Nila Rafiq; Zobair M Younossi
Journal:  Gut       Date:  2010-07-26       Impact factor: 23.059

9.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

10.  Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study.

Authors:  Ji Cheol Bae; Eun Jung Rhee; Won Young Lee; Se Eun Park; Cheol Young Park; Ki Won Oh; Sung Woo Park; Sun Woo Kim
Journal:  Diabetes Care       Date:  2011-01-28       Impact factor: 19.112

View more
  73 in total

1.  Sonographic Features of the Liver Among Females with Type 2 Diabetes.

Authors:  Bárbara L Riestra-Candelaria; Loida A González-Rodríguez; Wilma Rodriguez-Mojica; Luis E Vázquez-Quiñones; Juan Carlos Jorge
Journal:  J Diagn Med Sonogr       Date:  2019-03-08

2.  Effects of statins on the risk of hepatocellular carcinoma.

Authors:  Pejman G Mansourian; Masato Yoneda; M Krishna Rao; Fernando J Martinez; Emmanuel Thomas; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

3.  A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.

Authors:  Shuai Xue; Jianli Yin; Jiawei Shao; Yuanhuan Yu; Linfeng Yang; Yidan Wang; Mingqi Xie; Martin Fussenegger; Haifeng Ye
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

Review 4.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

5.  Uncovering the beginning of diabetes: the cellular redox status and oxidative stress as starting players in hyperglycemic damage.

Authors:  João Soeiro Teodoro; Ana Patrícia Gomes; Ana Teresa Varela; Filipe Valente Duarte; Anabela Pinto Rolo; Carlos Marques Palmeira
Journal:  Mol Cell Biochem       Date:  2013-01-08       Impact factor: 3.396

Review 6.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 7.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

Review 8.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Authors:  Ludovico Abenavoli; Natasa Milic; Valentina Peta; Francesco Alfieri; Antonino De Lorenzo; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality.

Authors:  Altan Onat; Günay Can; Ayşem Kaya; Tuğba Akbaş; Fatma Özpamuk-Karadeniz; Barış Şimşek; Hakan Çakır; Hüsniye Yüksel
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

10.  Gastrointestinal complications of diabetes mellitus.

Authors:  Babu Krishnan; Shithu Babu; Jessica Walker; Adrian B Walker; Joseph M Pappachan
Journal:  World J Diabetes       Date:  2013-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.